

# Gastric Ulcers - Pipeline Review, H1 2020

<https://marketpublishers.com/r/GDAE412FAA9EN.html>

Date: March 2020

Pages: 53

Price: US\$ 2,000.00 (Single User License)

ID: GDAE412FAA9EN

## Abstracts

Gastric Ulcers - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H1 2020, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape.

Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is *Helicobacter pylori* bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Ulcers - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gastric Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 3 and 2 respectively. Similarly, the

Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gastric Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Ulcers (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Gastric Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gastric Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gastric Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Ulcers (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gastric Ulcers (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gastric Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Gastric Ulcers - Overview

Gastric Ulcers - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gastric Ulcers - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastric Ulcers - Companies Involved in Therapeutics Development

Axsome Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

FortuneRock (China) Ltd

Hunan Mingrui Pharmaceutical Co Ltd

Hunan Sailong Pharmaceutical Co Ltd

Jiangsu Aosaikang Pharmaceutical Co Ltd

PharmaKing Co Ltd

RaQualia Pharma Inc

Sam-A Pharm Co Ltd

XuanZhu Pharma Co Ltd

Gastric Ulcers - Drug Profiles

(meloxicam + esomeprazole) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexlansoprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexlansoprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexuprazan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-3571 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pantoprazole sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMKS-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SA-15001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9X0123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastric Ulcers - Dormant Projects

Gastric Ulcers - Discontinued Products

Gastric Ulcers - Product Development Milestones

Featured News & Press Releases

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium

Category 1.1 New Drug Clinical Studies

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)

Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court

Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court

Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals

Oct 23, 2001: Prilosec US litigation

May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec

May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent

Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement

Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada

Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Gastric Ulcers, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Gastric Ulcers - Pipeline by Axsome Therapeutics Inc, H1 2020  
Gastric Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020  
Gastric Ulcers - Pipeline by FortuneRock (China) Ltd, H1 2020  
Gastric Ulcers - Pipeline by Hunan Mingrui Pharmaceutical Co Ltd, H1 2020  
Gastric Ulcers - Pipeline by Hunan Sailong Pharmaceutical Co Ltd, H1 2020  
Gastric Ulcers - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H1 2020  
Gastric Ulcers - Pipeline by PharmaKing Co Ltd, H1 2020  
Gastric Ulcers - Pipeline by RaQualia Pharma Inc, H1 2020  
Gastric Ulcers - Pipeline by Sam-A Pharm Co Ltd, H1 2020  
Gastric Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H1 2020  
Gastric Ulcers - Dormant Projects, H1 2020  
Gastric Ulcers - Dormant Projects, H1 2020 (Contd..1), H1 2020  
Gastric Ulcers - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Gastric Ulcers, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products by Targets, H1 2020  
Number of Products by Stage and Targets, H1 2020  
Number of Products by Mechanism of Actions, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Axsome Therapeutics Inc  
Daewoong Pharmaceutical Co Ltd  
FortuneRock (China) Ltd  
Hunan Mingrui Pharmaceutical Co Ltd  
Hunan Sailong Pharmaceutical Co Ltd  
Jiangsu Aosaikang Pharmaceutical Co Ltd  
PharmaKing Co Ltd  
RaQualia Pharma Inc  
Sam-A Pharm Co Ltd  
XuanZhu Pharma Co Ltd



## I would like to order

Product name: Gastric Ulcers - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/GDAE412FAA9EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDAE412FAA9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970